{"id":"lutetium-lu-177-dotatate","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Myelosuppression (anemia, thrombocytopenia, leukopenia)"},{"rate":null,"effect":"Renal toxicity"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":{"chemblId":"CHEMBL4297545","moleculeType":"Protein","molecularWeight":"1609.57"},"_dailymed":{"setId":"72d1a024-00b7-418a-b36e-b2cb48f2ab55","title":"LUTATHERA (LUTETIUM LU 177 DOTATATE) INJECTION [ADVANCED ACCELERATOR APPLICATIONS USA, INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug consists of the peptide dotatate labeled with lutetium-177, a beta-emitting radioisotope. Dotatate binds with high affinity to somatostatin receptor subtype 2 (SSTR2) expressed on neuroendocrine tumor cells. Once bound, the lutetium-177 delivers localized radiation directly to tumor cells, causing DNA damage and cell death while minimizing exposure to healthy tissue.","oneSentence":"Lutetium Lu 177 Dotatate is a radioactive peptide that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation to kill them.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:12:55.717Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs)"},{"name":"Somatostatin receptor-positive thoracic neuroendocrine tumors"}]},"trialDetails":[{"nctId":"NCT05687123","phase":"PHASE1","title":"Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-08-14","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Pancreatic Neoplasm, Stage III Pancreatic Neuroendocrine Tumor AJCC v8","enrollment":24},{"nctId":"NCT04665739","phase":"PHASE2","title":"Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-02-03","conditions":"Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm","enrollment":70},{"nctId":"NCT04261855","phase":"PHASE1, PHASE2","title":"Targeted Therapy and Avelumab in Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2020-10-08","conditions":"Metastatic Merkel Cell Carcinoma","enrollment":19},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":"Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":100},{"nctId":"NCT04750954","phase":"PHASE1","title":"Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-07-22","conditions":"Neuroendocrine Neoplasm","enrollment":29},{"nctId":"NCT05691465","phase":"PHASE2","title":"Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-12-27","conditions":"Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Prostate Small Cell Neuroendocrine Carcinoma","enrollment":30},{"nctId":"NCT05724108","phase":"PHASE2","title":"Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-30","conditions":"Metastatic Neuroendocrine Tumor","enrollment":94},{"nctId":"NCT06955169","phase":"PHASE2","title":"Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment","status":"RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2025-12-24","conditions":"Intracranial Meningioma","enrollment":153},{"nctId":"NCT04727723","phase":"","title":"Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-03-09","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":164},{"nctId":"NCT06122610","phase":"PHASE1","title":"Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2025-03-07","conditions":"Neuroendocrine Tumors, Somatostatin Receptor-positive Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT05142696","phase":"PHASE1, PHASE2","title":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-13","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT05109728","phase":"PHASE1","title":"A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Glioblastoma","enrollment":65},{"nctId":"NCT03971461","phase":"PHASE2","title":"Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2019-05-15","conditions":"Meningioma","enrollment":32},{"nctId":"NCT06379217","phase":"PHASE1","title":"NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-07-29","conditions":"Metastatic Neuroendocrine Prostate Cancer","enrollment":31},{"nctId":"NCT06784752","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-05-30","conditions":"Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)","enrollment":240},{"nctId":"NCT07150546","phase":"PHASE1","title":"Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-10-14","conditions":"Digestive System Neuroendocrine Tumor, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Digestive System Neuroendocrine Tumor G1","enrollment":15},{"nctId":"NCT03206060","phase":"PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-10-10","conditions":"Pheochromocytoma, Paraganglioma, Neuroendocrine Tumors","enrollment":130},{"nctId":"NCT04711135","phase":"PHASE2","title":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2022-08-31","conditions":"Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":11},{"nctId":"NCT04954820","phase":"PHASE2","title":"Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-10-18","conditions":"Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease","enrollment":146},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT05987176","phase":"PHASE2","title":"Comparison of Adjuvant Treatment With 177Lu-DOTATATE to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2024-08-02","conditions":"Neuroendocrine Tumor G1 (NET G1)/Carcinoid, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT06663072","phase":"PHASE1","title":"Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2024-12-13","conditions":"Metastatic Pancreatic Neuroendocrine Tumor","enrollment":25},{"nctId":"NCT03691064","phase":"","title":"Post-Authorization Long-Term Safety Study of LUTATHERA","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2018-11-28","conditions":"Neuroendocrine Tumors","enrollment":1014},{"nctId":"NCT04234568","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-20","conditions":"Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Neuroendocrine Tumor","enrollment":31},{"nctId":"NCT05844332","phase":"","title":"LUTATHERA Injection General Use Result Survey","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-17","conditions":"Somatostatin Receptor-positive Neuroendocrine Tumor","enrollment":347},{"nctId":"NCT04086485","phase":"PHASE1, PHASE2","title":"Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-10-03","conditions":"Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms","enrollment":56},{"nctId":"NCT06016855","phase":"PHASE4","title":"Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Vanderbilt-Ingram Cancer Center","startDate":"2024-05-31","conditions":"Digestive System Neuroendocrine Tumor G1, Digestive System Neuroendocrine Tumor G2, Metastatic Digestive System Neuroendocrine Neoplasm","enrollment":6},{"nctId":"NCT04082520","phase":"PHASE2","title":"Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2020-04-14","conditions":"Grade 1 Meningioma, Grade 2 Meningioma, Grade 3 Meningioma","enrollment":41},{"nctId":"NCT02743741","phase":"NA","title":"Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2016-07-15","conditions":"Neuroendocrine Tumors","enrollment":195},{"nctId":"NCT05178693","phase":"PHASE1","title":"Lutathera and ASTX727 in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2022-04-25","conditions":"Neuroendocrine Tumors","enrollment":27},{"nctId":"NCT03966651","phase":"PHASE1","title":"A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors.","status":"RECRUITING","sponsor":"Institut Claudius Regaud","startDate":"2023-04-17","conditions":"Neuroblastoma","enrollment":18},{"nctId":"NCT04529044","phase":"PHASE2","title":"177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-12-01","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma","enrollment":10},{"nctId":"NCT05278208","phase":"PHASE1, PHASE2","title":"Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-11-21","conditions":"High Grade Glioma, Meningioma, Embryonal Tumor","enrollment":65},{"nctId":"NCT06256705","phase":"NA","title":"Multi-modal Characterisation of Gastroenteropancreatic Neuroendocrine Tumours (GEP-NETs) Treated With Targeted Radionuclide Therapy (TRT): Prospective Interventional Multicentre National Cohort","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-03-25","conditions":"Gastroenteropancreatic Neuroendocrine Tumor, Radiotherapy","enrollment":80},{"nctId":"NCT07185672","phase":"PHASE3","title":"PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)","status":"RECRUITING","sponsor":"Tata Memorial Hospital","startDate":"2019-08-07","conditions":"Neuroendocrine Neoplasia's (NENs), Neuroendocrine Tumor GEP Grade 1-3, Neuroendocrine Gastroenteropancreatic Tumour","enrollment":162},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT04609592","phase":"PHASE1","title":"Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery","status":"RECRUITING","sponsor":"Stanford University","startDate":"2021-03-17","conditions":"Gastroenteropancreatic Neuroendocrine Tumor","enrollment":10},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":"Neuroendocrine Tumors","enrollment":196},{"nctId":"NCT06398444","phase":"PHASE2, PHASE3","title":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2024-06-11","conditions":"Advanced Neuroendocrine Neoplasm","enrollment":74},{"nctId":"NCT03457948","phase":"PHASE2","title":"Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nicholas Fidelman, MD","startDate":"2018-08-27","conditions":"Metastatic Malignant Neoplasm in the Liver, Neuroendocrine Neoplasm","enrollment":32},{"nctId":"NCT06878664","phase":"PHASE3","title":"Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2025-06-12","conditions":"Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs)","enrollment":166},{"nctId":"NCT01876771","phase":"PHASE2","title":"A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2014-04-29","conditions":"Carcinoma, Neuroendocrine","enrollment":500},{"nctId":"NCT04837885","phase":"PHASE2","title":"Intra-arterial Hepatic (IAH) Infusion of Radiolabelled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-09-24","conditions":"Neuroendocrine Tumor, Liver Metastases, Neuroendocrine Gastroenteropancreatic Tumour","enrollment":23},{"nctId":"NCT06395402","phase":"PHASE2","title":"177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry","status":"RECRUITING","sponsor":"University of Iowa","startDate":"2024-05-03","conditions":"Neuroendocrine Tumors, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2","enrollment":120},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":"NETS Ga68 Lu177","enrollment":184},{"nctId":"NCT07012330","phase":"PHASE2","title":"Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients","status":"TERMINATED","sponsor":"Erasmus Medical Center","startDate":"2007-03-01","conditions":"Neuroendocrine (NE) Tumors","enrollment":111},{"nctId":"NCT05870423","phase":"PHASE1","title":"Improving Peptide Receptor Radionuclide Therapy With PARP Inhibitors","status":"RECRUITING","sponsor":"Erasmus Medical Center","startDate":"2022-06-01","conditions":"Neuroendocrine Tumors, Peptide Receptor Radionuclide Therapy","enrollment":24},{"nctId":"NCT05583708","phase":"PHASE2","title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","status":"RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2023-08-03","conditions":"Merkel Cell Carcinoma","enrollment":18},{"nctId":"NCT04544098","phase":"EARLY_PHASE1","title":"Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":"Neuroendocrine Tumors, Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors","enrollment":10},{"nctId":"NCT02230176","phase":"PHASE2","title":"Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2015-02","conditions":"Pancreatic Neuroendocrine Carcinoma","enrollment":84},{"nctId":"NCT05247905","phase":"PHASE2","title":"Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-02-16","conditions":"Metastatic Pancreatic Neuroendocrine Tumor, Unresectable Pancreatic Neuroendocrine Carcinoma","enrollment":31},{"nctId":"NCT06126588","phase":"PHASE2","title":"Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical Trial","status":"RECRUITING","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-29","conditions":"Meningioma","enrollment":28},{"nctId":"NCT05249114","phase":"PHASE1","title":"Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-12-28","conditions":"Neuroendocrine Tumors","enrollment":6},{"nctId":"NCT06389097","phase":"","title":"SPECT Imaging for Pharmacokinetics and dosimEtry Towards TREATment Optimization","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-02-03","conditions":"Prostate Cancer, Advanced Cancer","enrollment":80},{"nctId":"NCT06460467","phase":"","title":"Semi-automatic Segmentation Method for Determining 177Lu-DOTATATE Tumor Dosimetry","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-01","conditions":"Meningioma","enrollment":25},{"nctId":"NCT06614205","phase":"","title":"Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2024-11-01","conditions":"Meningioma of Brain","enrollment":11},{"nctId":"NCT05053854","phase":"PHASE1","title":"PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Peter MacCallum Cancer Centre, Australia","startDate":"2021-12-08","conditions":"Neuroendocrine Tumors","enrollment":24},{"nctId":"NCT04903899","phase":"PHASE2","title":"177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma","status":"RECRUITING","sponsor":"Jakob Stenman","startDate":"2021-05-19","conditions":"Neuroblastoma Recurrent, Neuroblastoma","enrollment":24},{"nctId":"NCT04524442","phase":"PHASE4","title":"Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2021-01-25","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":42},{"nctId":"NCT02489604","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2013-12","conditions":"Neuroendocrine Tumors","enrollment":70},{"nctId":"NCT02736500","phase":"PHASE1, PHASE2","title":"Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2015-09-02","conditions":"Neuroendocrine Tumors, Gastro Entero Pancreatic Neuroendocrine Tumors","enrollment":39},{"nctId":"NCT04917484","phase":"PHASE2","title":"Dosimetry Based PRRT Versus Standard Dose PRRT With Lu-177-DOTATOC in NEN Patients","status":"RECRUITING","sponsor":"Tine Gregersen, MD","startDate":"2020-02-01","conditions":"Neuroendocrine Neoplasm","enrollment":100},{"nctId":"NCT05610826","phase":"PHASE1, PHASE2","title":"Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2023-03-07","conditions":"Pancreatic Neuroendocrine Tumor, Pancreas Cancer","enrollment":""},{"nctId":"NCT06607692","phase":"PHASE2","title":"Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).","status":"RECRUITING","sponsor":"Fundación de investigación HM","startDate":"2024-10","conditions":"Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma","enrollment":25},{"nctId":"NCT02236910","phase":"PHASE2","title":"An Open Label Registry Study of Lutetium-177 (DOTA0, TYR3) Octreotate (Lu-DOTA-TATE) Treatment in Patients with Somatostatin Receptor Positive Tumours","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2014-07","conditions":"Neuroendocrine Carcinoma","enrollment":66},{"nctId":"NCT03454763","phase":"PHASE2","title":"Optimizing the Interval Between Cycles of PRRT with 177lu-dotatate in Sstr2 Positive Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2016-05-26","conditions":"Neuroendocrine Tumors","enrollment":618},{"nctId":"NCT02754297","phase":"PHASE2","title":"Personalized PRRT of Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2016-04-12","conditions":"Neuroendocrine Tumors, Carcinoid Tumor, Carcinoma, Neuroendocrine","enrollment":275},{"nctId":"NCT04946305","phase":"","title":"A Post Marketing Surveillance on Lutathera® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"Somatostatin Receptor-positive GEP-NET","enrollment":89},{"nctId":"NCT04614766","phase":"PHASE1, PHASE2","title":"A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors","status":"WITHDRAWN","sponsor":"David Bushnell","startDate":"2022-09-30","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor, Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT04467567","phase":"NA","title":"Dosimetry Using a CZT-camera Following LUTATHERA® Therapy","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2020-11-27","conditions":"Dosimetry","enrollment":15},{"nctId":"NCT06121271","phase":"PHASE2","title":"Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed Indications","status":"NOT_YET_RECRUITING","sponsor":"University College, London","startDate":"2023-12-18","conditions":"Bronchial and Thymic Neuroendocrine Tumour, Paraganglioma/ Phaeochromocytoma, Medullary Thyroid Carcinoma","enrollment":110},{"nctId":"NCT05537675","phase":"","title":"Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2022-10-01","conditions":"Refractory Meningioma","enrollment":20},{"nctId":"NCT05198479","phase":"PHASE2","title":"Phase II 177Lu-DOTATATE Study in Metastatic NPC With a Safety Run-in","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2023-05-05","conditions":"Metastatic Nasopharyngeal Cancer","enrollment":25},{"nctId":"NCT04543955","phase":"PHASE2","title":"Telotristat With Lutathera in Neuroendocrine Tumors","status":"TERMINATED","sponsor":"Lowell Anthony, MD","startDate":"2021-09-13","conditions":"Neuroendocrine Tumors","enrollment":1},{"nctId":"NCT04385992","phase":"PHASE2","title":"Neoadjuvant PRRT With 177Lu-DOTATATE Followed by Surgery for Resectable PanNET","status":"COMPLETED","sponsor":"IRCCS San Raffaele","startDate":"2020-03-09","conditions":"Neuroendocrine Tumors","enrollment":31},{"nctId":"NCT05894486","phase":"PHASE2","title":"Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2023-06-05","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT05816720","phase":"","title":"Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-09-01","conditions":"Neuroendocrine Tumor","enrollment":31},{"nctId":"NCT05513469","phase":"NA","title":"Biomarker Identification of Radionuclide Therapy-induced Radiation Responses","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2023-01-01","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT05785663","phase":"","title":"AminoMedixTM for Kidney Protection During Radionuclide Therapy","status":"COMPLETED","sponsor":"Excel Diagnostics and Nuclear Oncology Center","startDate":"2014-08-08","conditions":"Radiation Nephropathy","enrollment":28},{"nctId":"NCT01237457","phase":"PHASE2","title":"177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms","status":"COMPLETED","sponsor":"Ebrahim S Delpassand","startDate":"2010-10-27","conditions":"Neuroendocrine Tumors","enrollment":143},{"nctId":"NCT04922801","phase":"","title":"Optimising Molecular Radionuclide Therapy","status":"COMPLETED","sponsor":"King's College London","startDate":"2021-12-09","conditions":"Neuroendocrine Tumors, Hyperthyroidism, Thyroid Cancer","enrollment":50},{"nctId":"NCT04949282","phase":"","title":"Spanish Series of Patients Treated With the Radionuclide Lutetium177","status":"RECRUITING","sponsor":"Sociedad Española de Medicina Nuclear e Imagen Molecular","startDate":"2021-05-10","conditions":"Neuroendocrine Tumors, Intestinal Neoplasms, Pancreatic Neoplasms","enrollment":5000},{"nctId":"NCT01842165","phase":"PHASE3","title":"177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs","status":"COMPLETED","sponsor":"Jules Bordet Institute","startDate":"2013-05","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":37},{"nctId":"NCT03590119","phase":"PHASE2, PHASE3","title":"Intra-arterial Lutetium-177-dotatate for Treatment of Patients With Neuro-endocrine Tumor Liver Metastases","status":"COMPLETED","sponsor":"Marnix Lam","startDate":"2018-08-01","conditions":"Neuroendocrine Tumors, Liver Metastases","enrollment":26},{"nctId":"NCT04525638","phase":"PHASE2","title":"A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours","status":"UNKNOWN","sponsor":"Fundación de investigación HM","startDate":"2020-06-29","conditions":"Neuroendocrine Tumours (NET), Neuroendocrine Carcinomas (NEC)","enrollment":30},{"nctId":"NCT01578239","phase":"PHASE3","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2012-09-06","conditions":"Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour","enrollment":231},{"nctId":"NCT03923257","phase":"PHASE1, PHASE2","title":"Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2020-08-04","conditions":"Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma","enrollment":""},{"nctId":"NCT03325816","phase":"PHASE1, PHASE2","title":"Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2017-11-20","conditions":"Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage","enrollment":9},{"nctId":"NCT04106843","phase":"PHASE2","title":"Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-06-13","conditions":"Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma","enrollment":""},{"nctId":"NCT04039516","phase":"PHASE2","title":"Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy","status":"UNKNOWN","sponsor":"King's College Hospital NHS Trust","startDate":"2020-10","conditions":"Carcinoid Heart Disease, Carcinoid Syndrome, Carcinoid Tumor","enrollment":20},{"nctId":"NCT02067988","phase":"PHASE2","title":"Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy Study","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2014-02","conditions":"Neuroendocrine Tumors","enrollment":34},{"nctId":"NCT04029428","phase":"PHASE2","title":"Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression","status":"UNKNOWN","sponsor":"University of Warmia and Mazury","startDate":"2004-11-02","conditions":"Neuroendocrine Tumors","enrollment":150},{"nctId":"NCT03422029","phase":"PHASE2","title":"Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients","status":"UNKNOWN","sponsor":"Peking University","startDate":"2018-01-31","conditions":"Neuroendocrine Tumors","enrollment":20},{"nctId":"NCT02125474","phase":"NA","title":"Efficacy of 177-Lu-DOTA 0, Tyr 3 Octreotate","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia, Columbia","startDate":"2013-11","conditions":"Neuroendocrine Tumors","enrollment":39},{"nctId":"NCT02705313","phase":"","title":"EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx","status":"APPROVED_FOR_MARKETING","sponsor":"Advanced Accelerator Applications","startDate":"","conditions":"Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT01099228","phase":"NA","title":"Combination Targeted Radiotherapy in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"David Bushnell","startDate":"2006-09","conditions":"Neuroendocrine Tumors","enrollment":2},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":"Gastro-intestinal Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT01201096","phase":"","title":"Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)","status":"UNKNOWN","sponsor":"University of Jena","startDate":"2010-09","conditions":"Liver, Metastasis, Neuroendocrine Tumors","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["177 Lu-DOTA-TATE","177 Lu-DOTA-Tyr3-Octreotate","177Lu-DOTA0-Tyr3-Octreotate","Lutathera","Lutetium (177Lu) Oxodotreotide"],"phase":"marketed","status":"active","brandName":"Lutetium Lu 177 Dotatate","genericName":"Lutetium Lu 177 Dotatate","companyName":"National Cancer Institute (NCI)","companyId":"national-cancer-institute-nci","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lutetium Lu 177 Dotatate is a radioactive peptide that binds to somatostatin receptors on neuroendocrine tumor cells and delivers targeted radiation to kill them. Used for Somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), Somatostatin receptor-positive thoracic neuroendocrine tumors.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}